Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors

Leukemia Research

Volumn 31, Issue 2, 2007, Pages 211-220

  Biedermann, Bjoern ^a   Gil, Diana ^a   Bowen, David T ^b   Crocker, Paul R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

AML; CD33; Endocytosis; Surface expression

Indexed keywords

CD33 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; ENDOCYTOSIS; GENETIC TRANSFECTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; STEM CELL;

ACUTE DISEASE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; LECTINS; LEUKEMIA, MYELOID; TUMOR MARKERS, BIOLOGICAL;

EID: 33845201539     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.05.026     Document Type: Article

References (28)

1. Jordan C.T., and Guzman M.L. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 23 (2004) 7178-7187
2. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33 (1976) 451-458
3. Bennett J.M. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72 (2000) 131-133
4. Taussig D.C., Pearce D.J., Simpson C., Rohatiner A.Z., Lister T.A., Kelly G., et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106 (2005) 4086-4092
5. Linenberger M.L. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19 (2005) 176-182
6. Varki A., and Angata T. Siglecs-the major sub-family of I-type lectins. Glycobiology (2005)
7. Crocker P.R. Siglecs in innate immunity. Curr Opin Pharmacol 5 (2005) 431-437
8. Cornish A.L., Freeman S., Forbes G., Ni J., Zhang M., Cepeda M., et al. Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Blood 92 (1998) 2123-2132
9. Nicoll G., Ni J., Liu D., Klenerman P., Munday J., Dubock S., et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem 274 (1999) 34089-34095
10. Patel N., Brinkman-Van der Linden E.C., Altmann S.W., Gish K., Balasubramanian S., Timans J.C., et al. OB-BP1/Siglec-6: a leptin-and sialic acid-binding protein of the immunoglobulin superfamily. J Biol Chem 274 (1999) 22729-22738
11. Floyd H., Ni J., Cornish A.L., Zeng Z., Liu D., Carter K.C., et al. Siglec-8: a novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem 275 (2000) 861-866
12. Kikly K.K., Bochner B.S., Freeman S.D., Tan K.B., Gallagher K.T., D'Alessio K.J., et al. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol 105 (2000) 1093-1100
13. Zhang J.Q., Nicoll G., Jones C., and Crocker P.R. Siglec-9: a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem 275 (2000) 22121-22126
14. Munday J., Kerr S., Ni J., Cornish A.L., Zhang J.Q., Nicoll G., et al. Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor. Biochem J 355 (2001) 489-497
15. Angata T., Kerr S.C., Greaves D.R., Varki N.M., Crocker P.R., and Varki A. Cloning and characterization of human Siglec-11. A recently evolved signaling that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J Biol Chem 277 (2002) 24466-24474
16. Lock K., Zhang J., Lu J., Lee S.H., and Crocker P.R. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. Immunobiology 209 (2004) 199-207
17. Avril T., Floyd H., Lopez F., Vivier E., and Crocker P.R. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related siglecs expressed on human monocytes and NK cells. J Immunol 173 (2004) 6841-6849
18. Avril T., Freeman S.D., Attrill H., Clarke R.G., and Crocker P.R. Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation. J Biol Chem 280 (2005) 19843-19851
19. Walter R.B., Raden B.W., Kamikura D.M., Cooper J.A., and Bernstein I.D. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 105 (2005) 1295-1302
20. Nutku E., Aizawa H., Hudson S.A., and Bochner B.S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101 (2003) 5014-5020
21. von Gunten S., Yousefi S., Seitz M., Jakob S.M., Schaffner T., Seger R., et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 106 (2005) 1423-1431
22. Balaian L., Zhong R.K., and Ball E.D. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol 31 (2003) 363-371
23. Virgo P., Denning-Kendall P.A., Erickson-Miller C.L., Singha S., Evely R., Hows J.M., et al. Identification of the CD33-related siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias. Br J Haematol 123 (2003) 420-430
24. Vitale C., Romagnani C., Puccetti A., Olive D., Costello R., Chiossone L., et al. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Sci USA 98 (2001) 5764-5769
25. Blair A., Hogge D.E., Ailles L.E., Lansdorp P.M., and Sutherland H.J. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89 (1997) 3104-3112
26. van der Velden V.H., Boeckx N., Jedema I., te Marvelde J.G., Hoogeveen P.G., Boogaerts M., et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg™) treatment in acute myeloid leukemia patients. Leukemia 18 (2004) 983-988
27. Angata T., and Varki A. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways. J Biol Chem 275 (2000) 22127-22135
28. Connolly N.P., Jones M., and Watt S.M. Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions. Br J Haematol 119 (2002) 221-238